Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

19.19
-1.1200-5.51%
Pre-market: 19.400.2100+1.09%07:50 EDT
Volume:5.14M
Turnover:100.41M
Market Cap:3.58B
PE:-5.73
High:20.16
Open:19.38
Low:18.97
Close:20.31
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:1.07
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:5.10
PE(LYR):-5.52

Loading ...

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08

Novartis Twin Drug Setbacks Pile Pressure on Pipeline, CEO

Reuters
·
Sep 08

Dyne Therapeutics Advances Four DMD Exon-Skipping Candidates into IND-Enabling Studies

Reuters
·
Sep 03

Dyne Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Universal Health (UHS)

TIPRANKS
·
Aug 25

Dyne Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule

Reuters
·
Aug 21

Dyne Therapeutics Grants New-Hire Equity Awards for 212,500 Shares Under Inducement Plan

Reuters
·
Aug 21

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 21

Dyne Therapeutics Director Jason P. Rhodes Disposes of Common Shares Worth $67.45 Million

Reuters
·
Aug 18

Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus

Simply Wall St.
·
Aug 09

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

MT Newswires Live
·
Aug 07

Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Aug 05

Dyne Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 31

RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 30

Anavex Life Sciences Q2 Net Loss Narrows on Lower R&D Costs

Reuters
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Mach7 Technologies (OtherTDMMF) and Dyne Therapeutics (DYN)

TIPRANKS
·
Jul 30

Dyne Therapeutics, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate

Benzinga Earnings
·
Jul 30

Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)

TIPRANKS
·
Jul 30

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire
·
Jul 30